Fig. 2From: Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trialsForest plots of pooled overall survival in patients with localized esophageal cancer. a 1-year overall survival. b 2-year overall survival. c 3-year overall survival. d 5-year overall survival. CET, cetuximabBack to article page